

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-7. (Canceled)

8. (Currently Amended) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT<sub>4</sub> receptor ligand, having a structure selected from the group consisting of NH<sub>3</sub><sup>+</sup>-norleucine-tyrosine-isoleucine-histidine-COO<sup>-</sup> (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH<sub>2</sub> (SEQ ID NO: 1); and administering the AT<sub>4</sub> receptor ligand.

3  
2 9. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT<sub>4</sub> receptor ligand locally.

4  
2 10. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT<sub>4</sub> receptor ligand intravascularly.

5  
2 11. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT<sub>4</sub> receptor ligand intramuscularly.

6  
2 12. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT<sub>4</sub> receptor ligand intraperitoneally.

~~2~~ 7 13. (Allowed) The method of inhibiting angiogenesis according to claim ~~8~~ or claim ~~29~~, further comprising the delivery of the AT<sub>4</sub> receptor ligand subcutaneously.

~~2~~ 8 14. (Allowed) The method of inhibiting angiogenesis according to claim ~~8~~ or claim ~~29~~, further comprising the delivery of the AT<sub>4</sub> receptor ligand orally.

9 15. (Currently Amended) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT<sub>4</sub> receptor ligand, having a structure selected from the group consisting of: NH<sub>3</sub><sup>+</sup>-norleucine-tyrosine-isoleucine-histidine-COO<sup>-</sup> (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH<sub>2</sub> (SEQ ID NO: 1); and administering the AT<sub>4</sub> receptor ligand.

11 16. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ or claim ~~30~~, further comprising delivery of the AT<sub>4</sub> receptor ligand locally.

12 17. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ or claim ~~30~~, further comprising the delivery of the AT<sub>4</sub> receptor ligand intravascularly.

13 18. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ or claim ~~30~~, further comprising the delivery of the AT<sub>4</sub> receptor ligand intramuscularly.

14 19. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ or claim ~~30~~, further comprising the delivery of the AT<sub>4</sub> receptor ligand intraperitoneally.

- 15
20. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the step of applying the AT<sub>4</sub> receptor ligand subcutaneously 10
- 16
21. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the step of applying the AT<sub>4</sub> receptor ligand orally. 9 10
- 17
22. (Currently Amended) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT<sub>4</sub> receptor ligand, having a structure selected from the group consisting of: NH<sub>3</sub><sup>+</sup>-norleucine-tyrosine-isoleucine-histidine-COO<sup>-</sup> (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH<sub>2</sub> (SEQ ID NO: 1), and administering the AT<sub>4</sub> receptor ligand.
- 16 23. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT<sub>4</sub> receptor ligand locally to the tumor. 17 18
- 20 24. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT<sub>4</sub> receptor ligand intravascularly. 17 18
- 21 25. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT<sub>4</sub> receptor ligand intramuscularly. 17 18
- 22 26. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT<sub>4</sub> receptor ligand intraperitoneally. 17 18

*23*  
~~21.~~ (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ or claim ~~31~~, further comprising the delivery of the AT<sub>4</sub> receptor ligand subcutaneously. *17* *18*

*24*  
~~28.~~ (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT<sub>4</sub> receptor ligand orally.

*29.* (Currently Amended) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT<sub>4</sub> receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH<sub>2</sub>-NH<sub>2</sub>)<sup>3-4</sup>-histidine-proline-phenylalanine-COO<sup>-</sup> (SEQ ID NO: 3); and administering the AT<sub>4</sub> receptor ligand.

*10*  
~~30.~~ (Currently Amended) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT<sub>4</sub> receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH<sub>2</sub>-NH<sub>2</sub>)<sup>3-4</sup>-histidine-proline-phenylalanine-COO<sup>-</sup> (SEQ ID NO: 3); and administering the AT<sub>4</sub> receptor ligand.

*18*  
~~31.~~ (Currently Amended) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT<sub>4</sub> receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH<sub>2</sub>-NH<sub>2</sub>)<sup>3-4</sup>-histidine-proline-phenylalanine-COO<sup>-</sup> (SEQ ID NO: 3); and administering the AT<sub>4</sub> receptor ligand.